CNTA
Centessa Pharmaceuticals PLC ADR
NASDAQ: CNTA · HEALTHCARE · BIOTECHNOLOGY
$39.45
-0.03% today
Updated 2026-04-29
Market cap
$6.10B
P/E ratio
—
P/S ratio
406.76x
EPS (TTM)
$-1.46
Dividend yield
—
52W range
$11 – $40
Volume
3.0M
Centessa Pharmaceuticals PLC ADR (CNTA) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | — | $0.00 | $6.85M | $0.00 | $15.00M |
| Revenue growth (YoY) | — | — | — | — | — | -100.0% | — |
| Cost of revenue | — | — | $33995.00 | $130919.00 | $813139.00 | $942396.00 | — |
| Gross profit | — | — | $-33995.00 | $-131000.00 | $6.85M | $-942396.00 | $15.00M |
| Gross margin | — | — | — | — | 100.0% | — | 100.0% |
| R&D | $4.26M | $9.30M | $96.32M | $155.08M | $124.41M | $150.24M | $172.22M |
| SG&A | $790000.00 | $1.14M | $43.01M | $55.20M | $53.73M | $50.81M | $50.47M |
| Operating income | $-5.05M | $-10.44M | $-374.87M | $-212.26M | $-171.28M | $-201.06M | $-207.69M |
| Operating margin | — | — | — | — | -2499.4% | — | -1384.6% |
| EBITDA | $-5.05M | $-10.29M | $-139.30M | $-209.55M | $-165.43M | $-221.88M | $-207.69M |
| EBITDA margin | — | — | — | — | -2413.9% | — | -1384.6% |
| EBIT | $-5.05M | $-10.44M | $-139.33M | $-209.68M | $-166.24M | $-222.82M | — |
| Interest expense | $118000.00 | $378000.00 | $2.55M | $7.28M | $9.91M | $10.09M | $11.46M |
| Income tax | $223000.00 | $378000.00 | $114000.00 | $-747000.00 | $-25.06M | $2.84M | — |
| Effective tax rate | -4.4% | -3.7% | -0.0% | 0.3% | 14.2% | -1.2% | 0.0% |
| Net income | $-5.28M | $-10.66M | $-381.90M | $-216.21M | $-151.09M | $-235.76M | $-197.53M |
| Net income growth (YoY) | — | -101.8% | -3481.5% | +43.4% | +30.1% | -56.0% | +16.2% |
| Profit margin | — | — | — | — | -2204.7% | — | -1316.9% |